The drugs are currently used to control blood pressure in some diabetic patients, but this new study looked at whether the drugs could aid weight loss, both in people with diabetes and without. Further research into the risks and benefits of these drugs – both in people with diabetes and without – is required before they could be considered to be a possible treatment for weight loss in the wider population. They are not prescribed as weight loss drugs and not approved for the purposes of weight loss at present. Further research into the risks and benefits of these drugs is required before they could be considered to be weight loss treatments for wider population groups. The two GLP-1 R agonists, exenatide and liraglutide, are both administered by subcutaneous injection, and have a restricted licence for people with type 2 diabetes. For those with type 2 diabetes they also looked at the effect of the drugs on blood sugar control. The researchers say their review provides evidence that GLP-1 R agonists lead to weight loss in obese or overweight patients, irrespective of whether or not they have type 2 diabetes. They argue that the drugs should be considered in obese or overweight patients with diabetes, but stress that more research is needed on their effects in obese patients without diabetes. This was a large, well-conducted systematic review that combined the results of trials investigating whether glucagon-like peptide-1 receptor (GLP-1 R) agonists produce weight loss in overweight or obese people with or without type 2 diabetes. The review found that GLP-1 R agonists were associated with weight loss in both people with and without diabetes. In conclusion, as an accompanying editorial points out, further trials are needed to investigate the benefits as well as the risks of these new drugs – both in people with diabetes and without – before they could be considered as possible treatments for weight loss in wider population groups.
The diabetes drug liraglutide can help obese people who don't have diabetes lose weight and keep it off, new findings confirm. Researchers found that 63 percent of study participants given liraglutide for 56 weeks lost at least 5 percent of their body weight — the amount experts agree is needed to make a difference in obesity-related health problems — whereas just 27 percent of the placebo group lost that much. Liraglutide has been available in the United States for treating people with diabetes since 2010. The Food and Drug Administration approved liraglutide (at a higher dose than is used for diabetes) for treating obesity in December 2014. About 2,500 patients in the study were given liraglutide, and about 1,200 were given the placebo injections. After 56 weeks, the participants on liraglutide lost an average of 18.5 pounds, compared with 6.4 pounds for the people on the placebo. Among the patients on liraglutide, 33 percent lost at least 10 percent of their body weight, whereas just 11 percent of the placebo group lost that much. The most common side effects of the drug were nausea and diarrhea. Also, Pi-Sunyer said, patients will probably have to be on the drug indefinitely to maintain weight loss. Many of the people in the study who lost weight on liraglutide remained obese, Siraj said, although this doesn't mean they didn't benefit from losing weight. The patients who will likely benefit the most from liraglutide are those with diabetes, high blood pressure, cholesterol and other obesity-related problems, he added. The increased risk of gallstones and other problems associated with liraglutide should be investigated further, Siraj said.
If any of these effects persist or worsen, tell your doctor or pharmacist promptly. Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Tell your doctor about the reaction immediately. Talk with your doctor or pharmacist about what to do if you miss a meal. If you notice other effects not listed above, contact your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
Insulin and weight gain: Keep the pounds off. Insulin and weight gain often go hand in hand, but weight control is possible. If you need insulin therapy, here's how to minimize — or avoid — weight gain. Weight gain is a common side effect for people who take insulin — a hormone that regulates the absorption of sugar (glucose) by cells. The link between insulin and weight gain. When you take insulin, glucose is able to enter your cells, and glucose levels in your blood drop. But if you take in more calories than you need to maintain a healthy weight — given your level of activity — your cells will get more glucose than they need. What I need to know about diabetes medicines. National Institute of Diabetes and Digestive and Kidney Diseases. Department of Health and Human Services. Centers for Disease Control and Prevention. What I need to know about eating and diabetes.
Average weight loss on the highest dose of liraglutide was more than 7.2 kg at 20 weeks, which was 4.4 kg more than placebo. This was significantly more than the weight loss achieved on orlistat and it was clinically important. The researchers explain that liraglutide was developed for the treatment of type 2 diabetes. The participants who took liraglutide at all four doses lost significantly more weight than those on placebo or orlistat. Weight loss with liraglutide was 2.1 kg (95% CI 0.6-3.6) to 4.4 kg (2.9-6.0) greater than the weight lost with the placebo. In the group taking 3.0 mg liraglutide, 70 patients (76%) lost more than 5% of their weight. In the placebo group, 29 participants (30%) lost more than 5% of their weight. In the orlistat group, 42 (44%) lost more than 5% of their body weight. This well-conducted study has confirmed the efficacy of liraglutide and showed a dose response, i.e. The dose of liraglutide used in this trial is higher than the dose approved for use in diabetes. The researchers say that phase 3 studies with liraglutide at this dose (3.0 mg) are currently planned or underway.
There are several factors at work to lead you to believe that insulin is "to blame" for your weight gain. Then, when you start taking insulin and get your blood glucose under better control, you start over-retaining fluids initially to make up for your dehydration, which makes you think you've rapidly gained a lot of weight. Also, once you start taking insulin injections and start getting your blood glucose under control, you now have enough insulin circulating in your blood to help the glucose get into the body's cells where it can be used as energy. Your high blood glucose may have also made you feel more hungry because not all the food you were eating was able to get into the cells as energy to nourish the cells. Then, you started taking insulin — and continued to eat the same amount of food. Only this time, because your body has enough insulin to process the food you're eating, you gain weight. But once your blood glucose are in a more normal range, you're just using the food properly — and you gain weight. Letting your blood glucose run high can lead to long-term complications — and up and down weight problems when you try to bring your blood glucose back to a normal range.
Many therapies target specific symptoms of polycystic ovary syndrome (PCOS), but may not address the underlying cause. Because they cause women to menstruate regularly (and, thus, shed the endometrial lining), oral contraceptives as treatment for PCOS help to reduce a woman's risk of endometrial cancer. Many assisted-reproduction techniques are available for women who have difficulty conceiving because of PCOS. New evidence suggests that using medications which lower insulin levels in the blood may be effective in restoring menstruation and reducing some of the health risks associated with PCOS. Lowering insulin levels also helps to reduce the production of testosterone, thus diminishing many of the symptoms associated with excess testosterone: hair growth on the body, alopecia (scalp hair loss), acne, and, possibly, cardiovascular risk. These drugs are approved by the Food and Drug Administration (FDA) for the treatment of diabetes. Although they are not approved for treatment of PCOS, they have been shown to be effective for this purpose in many studies. It is approved by the FDA as a treatment for diabetes, but is not yet FDA-approved for use in treating PCOS. Physicians and scientists at the University of Chicago Medicine are actively pursuing new solutions for treating PCOS. Causes for the increased risk of diabetes in women with PCOS. The familial basis for PCOS and the related pattern of diabetes. Studies of the relationship between obstructive sleep apnea and PCOS. Losing weight can be quite challenging for women with PCOS. Weight loss achieved through dietary changes and exercise can help women with PCOS in several ways. Some women with PCOS find relief from symptoms through alternative therapies such as herbs, acupuncture, homeopathic remedies and other alternative approaches.
The trial compared glucose control of participants receiving daily injections of either basal insulin glargine or IDeg Lira, which is a mixture of insulin degludec and liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist. Treatment options for such patients are to either increase the basal insulin dose or to add additional shots of insulin at mealtimes. The downside of both of these approaches is weight gain and hypoglycemia (low blood sugar),” said the study’s lead author, Dr. “The clinical trial found that participants treated with the combination product had more improvement in their Hb A 1 C (hemoglobin A 1 C) test than those treated with basal insulin alone, they had weight loss rather than weight gain, and they had many fewer episodes of hypoglycemia,” she added. At the time they enrolled, study participants were taking an oral diabetes medication, metformin, as well as basal insulin glargine. Those who were assigned to the insulin glargine group had their insulin dose sequentially increased as high as necessary to bring their glucose levels under control. Participants who took the combination product saw their glucose levels drop faster. On average, the Hb A 1 C blood sugar level for participants on IDeg Lira dropped from 8.4 to 6.6. On average, the Hb A 1 C level for participants on insulin glargine dropped from 8.2 to 7.1. Those taking IDeg Lira lost an average of about 3 pounds compared with an average weight gain of nearly 4 pounds for the glargine group. Only 6.1 percent of participants on the combination product experienced confirmed episodes of nighttime hypoglycemia compared with 24.4 percent of the patients on the basal glargine. “The advantage of the combination product is that the treatment burden is the same as taking a basal insulin – one shot a day – but you are getting an additional product that works through a different mechanism and addresses different pathophysiologic defects of the disease. The liraglutide affects satiety and induces weight loss, while also stimulating insulin secretion.
This review will describe the individual classes of drugs and their effects on weight in patients with type 2 diabetes and, where pertinent, on patients with type 1 diabetes. In addition to drugs that have indications for treatment of type 2 diabetes, several anti-obesity drugs have been studied in patients with type 2 diabetes, for their effects on both weight and glucose control. 17 compared lispro and regular insulin at mealtimes and found no difference in weight gain between the two groups of patients with type 2 diabetes. The improved glucose control seen with these drugs may result in weight gain and in some cases substantial weight gain. 39 – 41 In a 3-month dose titration study of acarbose in patients with type 2 diabetes, no weight gain was seen in the three treatment groups when compared to placebo. 41 In a 6-month type 1 diabetes study of acarbose, an A 1 C decrease of 0.48% was observed, with a weight increase of 0.44 lb compared to a 0.22-lb weight gain in the placebo group. A 28-week trial that compared the addition of exenatide or glargine to patients already on oral agents found an equal decrease in A 1 C, with weight gain in the insulin cohort of 2.8 lb and weight loss in the exenatide cohort of 4.6 lb. Abnormalities in the production of amylin in conjunction with insulin abnormalities have been seen in both type 1 and type 2 diabetes. It has been studied in two small 3- and 4-month studies for weight loss in patients with type 2 diabetes. 74 Average weight loss was 8.1 lb over the placebo group and was associated with a decrease in A 1 C of 0.7% from a baseline of 8.5%. Less weight gain has been seen with inhaled insulin in patients on basal-bolus therapy, and the DPP-IVs have been associated with weight neutrality.
Diabetes and Weight Loss. First things first, discuss weight loss and an individual program with your health care team. Diet and weight loss. How does exercise help diabetes and weight loss? Exercise can help you to lose weight, by building muscle and burning calories. Weight loss and exercise. Could alternative weight loss therapies help? Alternative weight loss therapies can be beneficial to help support weight loss. Alternative weight loss therapies. Weight loss surgery is a serious undertaking but for some people it can be particularly beneficial. Weight loss surgery. Support to help you shed the weight.
He hopes the injection will be “the easy way” to weight loss and not require “any self-control.” Today’s medical students are trained to think of obesity as the new universal evil, because it promotes heart attack, stroke, diabetes, kidney failure and even arthritis (joints are crushed). Will this new injectable be the answer? The most notorious of these was fen-phen, a combination of fenfluramine and phentermine. The medication wakes up and protects the insulin-producing cells in the pancreas, which reduce blood sugar. And it lets food linger in the gut, as if it’s forcing you to eat slowly. (This slower transit through the gut also leads to the most common side effects, nausea and constipation.) What’s also smart is that the company is not just targeting diabetic patients, but also obese patients without diabetes, and – most amazingly – pre-diabetic patients. So how much weight do you lose on the new medication? Arya Sharma, professor and chair of obesity research at the University of Alberta.
WASHINGTON (Reuters) - Bariatric weight loss surgery on obese patients with type 2 diabetes helped many get their blood sugar to healthy levels and to no longer require any diabetes medicines, including insulin, three years after the procedure, according to data presented at a major medical meeting on Monday. The surgery also helped patients reduce the need for high blood pressure and cholesterol medicines and led to quality of life improvements compared with those who received medical weight-loss therapy, researchers found. The study called Stampede, which involved 150 obese patients who had poorly controlled type 2 diabetes for at least eight years, was conducted by Cleveland Clinic researchers. More than a third - 37.5 percent - of patients who underwent gastric bypass surgery and a quarter of those who had a sleeve gastrectomy procedure achieved blood sugar levels below the American Diabetes Association target and most no longer needed diabetes medicines, researchers said. That compared with just 5 percent of patients in the medical therapy group who got their A 1c blood sugar levels down to 6 percent or less. We do realize now that there may be a treatment that could end diabetes for some people and that's exciting," said Dr. At three years, only 5 to 10 percent of the surgery patients who had been using insulin still needed the treatment, compared with a comparable rate 55 percent in the medical therapy group. An estimated one third of Americans are considered obese and obesity is the leading contributor to the growing type 2 diabetes epidemic. But for some obese patients it may be worthwhile if it can stave off the toll of advanced diabetes that can include heart and kidney disease, as well as vascular problems that may lead to amputations or blindness. Data from the study was presented in 2012 showing the effect of the surgery on diabetes after one year. "The results were durable and they were far better than the people in the medical arm," said Kashyap. On average, gastric bypass patients lost 24 percent of their body weight and sleeve gastrectomy led to a 21 percent weight reduction, about five or six times more weight than the medical group, and more than has been demonstrated by new weight loss drugs that were not used in the study. Siegel, director of the Cardiac Noninvasive Laboratory at Cedars-Sinai Medical Center in Los Angeles, said the findings could lead to new targets for future diabetes drug development. Bypass patients also had significantly lower levels of albumin in the urine, a marker of kidney damage due to diabetes.
Why and how does losing weight help my diabetes? Lose weight and the liver has less work to do and can more precisely control blood sugar. Secondly, a diet designed for weight loss automatically has less sugar and fat in it than your normal diet. In Type 2 diabetics, loosing weight helps give the pancreas a break, which means it doesn't have to produce as much insulin and makes it easier for your body to use the insulin you do produce. If you take a diabetes medicine, losing weight lowers blood glucose and may allow you to reduce the amount you're taking, or quit taking it altogether. 2) in type II diabetes, losing weight and eating less foods reduce ambient blood sugar and insulin levels, helping improve the insulin resistance underlying the disorder. You can only upload files of type PNG, JPG or JPEG. You can only upload photos smaller than 5 MB. You can only upload videos smaller than 600 MB. You can only upload a photo or video.
Byetta and Bydureon are injectable drug pens used to control blood sugar in people with Type 2 diabetes. Food and Drug Administration (FDA) for the treatment of Type 2 diabetes . The drug is designed to work with diet and exercise to control blood sugar. Doctors typically prescribe Byetta or Bydureon to overweight people with Type 2 diabetes , because the drug also seems to help with weight loss. In three 30-week clinical trials, people who took Byetta had an average reduction of 1 percent in A 1 C – the amount of glucose concentrated in a person’s blood – after three years of treatment, and the drug was effective in managing Type 2 diabetes. In studies, Byetta increased the responsiveness of beta cells and allowed for more insulin production. Byetta significantly increased the first-phase insulin response in patients taking the drug. Along with lifestyle changes, Byetta is shown to help people with diabetes lose weight and better control their blood sugar levels. They administered Byetta to one group and a placebo to the other. Amylin and Eli Lilly say they do not encourage the “off-label” use – use not approved by the FDA – of the drug, but they funded studies of Byetta for weight loss in people with normal blood sugar.
New drug for type 2 diabetes helps with weight loss. A new once a day drug for type 2 diabetes which also helps patients lose weight and control blood pressure, has been launched in Britain. Victoza offers extra choice for people with type 2 diabetes which is one of the fastest growing diseases as the majority of cases are linked to obesity. Victoza, also known as liraglutide, helps patients to lose weight which is a major problem with type 2 diabetes because the disease is linked to obesity in many cases and the traditional drugs used to control it often encourage more weight gain. Professor Anthony Barnett, Professor of Medicine and Consultant Physician and Clinical Director of Diabetes and Endocrinology at Heart of England NHS Foundation Trust, Birmingham, said: "With Victoza patients with type 2 diabetes can be confident they are controlling their blood sugar, and may benefit from weight loss. There are around 2.5m people in Britain with diabetes, including type 1 which is not linked to obesity, and about 500,000 people do not know they have the condition. Cathy Moulton, Care Advisor at Diabetes UK, said: "Liraglutide widens the choice of treatments for people with Type 2 diabetes that not only offer improved blood glucose control but also aid weight loss.
The facts and conclusions presented may have since changed and may no longer be accurate. THURSDAY, May 29, 2014 (Health Day News) - A higher dose of the diabetes drug liraglutide (Victoza) may help obese people without the disease lose weight, a new study suggests. John Wilding, head of the department of obesity and endocrinology at the University of Liverpool in England. The results of the study were scheduled for presentation Thursday at the European Congress on Obesity in Sofia, Bulgaria. "A number of drugs used to treat type 2 diabetes tend to produce weight loss as one of their effects," said Katz, who was not involved in the study. This is predictable because the insulin resistance that precedes and often accompanies type 2 diabetes results in frequent hunger and weight gain. For the study, Wilding and colleagues randomly selected more than 3,700 obese and overweight adults to take daily injections of Victoza or a placebo. The researchers found that almost two-thirds of those taking Victoza lost 5 percent or more of their body weight, and one-third lost 10 percent or more. Among those taking the placebo, 27 percent lost 5 percent of their body weight or more, and one in 10 lost 10 percent or more. People taking Victoza also saw a drop in their blood sugar, blood pressure and cholesterol, the study found. Food and Drug Administration to approve Victoza for weight loss. The most common side effects were nausea and diarrhea. Most of these were mild and short-lived, the researchers said. Gallbladder and pancreas problems (pancreatitis) were more common among those taking Victoza, but the numbers were small. For more on obesity, visit the U.
Weight loss has many beneficial results for obese or overweight people: lower chances for heart disease or stroke, lowers blood pressure, triglyceride and cholesterol levels, improves osteoarthritis, lowers risk for type 2 diabetes. 5 HTP is a naturally occurring amino acid and is the immediate precursor of serotonin. When administered with Carbidopa, the 5 HTP increases brain serotonin which is effective in decreasing appetite, decreasing craving for food and for promoting weight loss. Armour Thyroid is a natural preparation - not a synthetic compound that provides both of the key thyroid hormones T 3 and T 4. Phentermine, a contraction for "phenyl-tertiary-butylamine" is an appetite suppresant of the amphetamine and phenethylamine class. It helps reduce weight in obese patients when used short-term and combined with exercise, diet and behavioral modification. For many hypothyroid patients, supplementing with T 4 alone does not contstitute adequate treatment and requires T 3 to be included. Chromium is a trace mineral and for certain individuals with high blood sugar levels, chromium may reduce insulin resistance, possibly reducing the risk of type 2 diabetes. Cobalamin or Vitamin B 12 helps to increase metabolism, gives a boost of energy and helps to fight stress and depression. Is a lipotropic combination containing the amino acid Methionine and two members of the Vitamin B family, Inositol and Choline. Vitamin B 6 helps with weight loss through a stimulating effect on the thyroid and by reducing water retention.
Oral anti‐diabetic agents for women with pre‐existing diabetes mellitus, impaired glucose tolerance or previous gestational diabetes mellitus. This means that management is important for women with diabetes and also for women with impaired glucose tolerance or previously diagnosed gestational diabetes. Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus. Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus. Obesity is closely related to type 2 diabetes and weight reduction is an important part of the care delivered to obese persons with diabetes. This review of drugs for weight loss among adults with type 2 diabetes revealed weight loss of between 2.0 and 5.1 kg for fluoxetine, orlistat and sibutramine at follow‐up of up to 57 weeks. There were few studies examining other drugs used for weight loss in populations with diabetes. Insulin degludec (Tresiba) for diabetes mellitus: Overview. Insulin degludec (trade name: Tresiba) has been approved in Germany since January 2013 for the treatment of type 1 and type 2 diabetes in adults.
Who should not use Victoza®? Do not use Victoza® if: It is not known if Victoza® can be used in people who have had pancreatitis. Victoza® is not a substitute for insulin and is not for use in people with type 1 diabetes or people with diabetic ketoacidosis. It is not known if Victoza® can be used with mealtime insulin. It is not known if Victoza® is safe and effective for use in children. Before using Victoza®, tell your health care provider if you: Do not mix insulin and Victoza® together in the same injection. You may give an injection of Victoza® and insulin in the same body area (such as your stomach area), but not right next to each other. Do not share your Victoza® pen with other people, even if the needle has been changed. What are the possible side effects of Victoza®? Stop using Victoza® and call your health care provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without vomiting. Your risk for getting low blood sugar may be higher if you use Victoza® with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin. The most common side effects of Victoza® may include headache, nausea, diarrhea, vomiting, and anti-liraglutide antibodies in your blood.
Diabetes drug Victoza may also help with weight loss: study. Combined with proper diet and exercise, trial participants shed a mean loss of 5.9% body weight. Its chemical name is liraglutide and when given in 3mg doses over a 56-week period, combined with proper diet and exercise, trial participants experienced a 5.9 percent mean loss of baseline body weight. Smaller doses of the drug led to a slightly reduced mean weight loss of 4.6 percent and the control group's mean weight loss was just two percent. If approved for use as a weight loss medication, the drug could serve an important patient group. "Weight loss and weight management are generally much harder for people who are overweight or obese and who also have type 2 diabetes," said Dr. "Given the challenges faced by this patient population, the 5.9% weight loss seen with liraglutide 3 mg in this study is impressive. Danish pharmaceutical company Novo Nordisk is currently awaiting response from the Food and Drug Administration (FDA) and European Medicines Association (EMA) for approval as a weight management drug for overweight and obese adults.
In new research published in the New England Journal of Medicine, Columbia University scientists found the drug liraglutide — brand name: Victoza — helped nearly two-thirds of people taking it for a little over a year to lose 5 percent of their body weight, Live Science reports. The Food and Drug Administration approved liraglutide (at a higher dose than is used for diabetes) to treat obesity in December 2014. For the new study, Pi-Sunyer and his colleagues randomly assigned 3,731 overweight or obese men and women to receive a 3.0-milligram dose of liraglutide daily, or a placebo shot. About 2,500 patients in the study were given liraglutide, and about 1,200 were given the placebo injections. After 56 weeks, the participants on liraglutide lost an average of 18.5 pounds, compared with 6.4 pounds for the people on the placebo. Among the patients on liraglutide, 33 percent lost at least 10 percent of their body weight. Also, Pi-Sunyer said, patients often have to be on the drug indefinitely to maintain weight loss.
Diabetes Drug May Spur Weight Loss in Obese People. THURSDAY, May 29, 2014 (Health Day News) - A higher dose of the diabetes drug liraglutide (Victoza) may help obese people without the disease lose weight, a new study suggests. "Liraglutide, an injection treatment already approved for diabetes treatment, can help reduce body weight in people with obesity when used at a higher dose than is usually used in diabetes ," said lead researcher Dr. "A number of drugs used to treat type 2 diabetes tend to produce weight loss as one of their effects," said Katz, who was not involved in the study. This is predictable because the insulin resistance that precedes and often accompanies type 2 diabetes results in frequent hunger and weight gain. Lowering blood sugar results in weight loss, he said.
A new, injectable weight-loss drug has been approved by the U. The agency on Tuesday approved Saxenda (liraglutide) for adults who are obese or for those who are overweight and have at least one weight-related health condition , such as high blood pressure, type 2 diabetes or high cholesterol. Patients taking the drug, made by Novo Nordisk, should still follow a low-calorie diet and exercise regularly, the FDA noted. Three clinical trials assessed the safety and effectiveness of the drug for weight loss. The trials involved roughly 4,800 obese and overweight people with and without other weight-related conditions. One clinical trial that involved patients without diabetes found that patients taking Saxenda had an average weight loss of 4.5 percent after one year. Of the people treated with the drug, 62 percent lost at least 5 percent of their body weight. The FDA added that patients should be examined to determine if Saxenda is working after 16 weeks of treatment. Those who do not lose at least 4 percent of their body weight by that time should stop taking the medication, the FDA said.
Research Review Shows Byetta and Victoza Can Help Overweight People Shed Pounds. 10, 2012 - Two drugs approved to treat type 2 diabetes may also aid weight loss in overweight people with or without diabetes , a new study shows. The drugs Byetta and Victoza mimic gut hormones that decrease appetite. The review reveals that the drugs helped overweight people without diabetes shed an average of 7 pounds and those with diabetes lose an average of 6 pounds when injected daily or weekly for at least five months. Vilsboll says the modest weight loss many of her diabetic patients see on the drugs helps encourage them to kick up their diet and exercise programs to lose even more weight . But Vilsboll says that side effect generally fades over time and doesn’t usually cause people to stop taking the medication. Experts who were not involved in the review say they are cautiously optimistic about the drugs’ prospects for weight loss. Weight loss by traditional means - diet and exercise - is extremely hard, and for people who are successful initially, it’s also very hard to maintain,” says Susan Spratt, MD, an endocrinologist and the director of diabetes services at Duke University Health System in Durham, N. “If we could use these drugs just in people with obesity and know that it’s safe, I think it would be a fantastic addition to our ability to treat obesity,” Spratt says.
THURSDAY, June 02, 2014 (Health Day News) — The diabetes drug liraglutide (Victoza) may help obese people without the disease lose weight, a new study suggests. In this test of its effectiveness as a diet aid, people taking Victoza for over a year lost an average of 8 percent of their body weight, compared with 2.6 percent shed by those taking a placebo (dummy drug), researchers found. “A number of drugs used to treat type 2 diabetes tend to produce weight loss as one of their effects,” said Katz, who was not involved in the study. This is predictable because the insulin resistance that precedes and often accompanies type 2 diabetes results in frequent hunger and weight gain. For the study, Wilding and colleagues randomly selected 3,731 obese and overweight adults to take daily injections of Victoza or a placebo. The researchers found that almost two-thirds of those taking Victoza lost 5 percent or more of their body weight, and one-third lost 10 percent or more. Among those taking the placebo, 27 percent lost 5 percent of their body weight or more, and one in 10 lost 10 percent or more. People taking Victoza also saw a drop in their blood sugar, blood pressure and cholesterol, the study found. Food and Drug Administration to approve Victoza for weight loss. The most common side effects were nausea and diarrhea. Most of these were mild and short-lived, the researchers said. Gallbladder and pancreas problems (pancreatitis) were more common among those taking Victoza, but the numbers were small.
The Dilemma of Weight Loss in Diabetes. Furthermore, for people with type 2 diabetes, the message often is that weight loss is the answer to improving glucose control: “If you just lose 20 lb, you won't need insulin.” What does research tell us about these issues, and what should our messages as health professionals be to people with diabetes? Is weight loss the complete answer for improving blood glucose control? The remainder of this editorial addresses what is known today about weight loss in general and how this information applies to people with diabetes. And, for people with diabetes, is weight loss the cure? Weight Loss in People With Diabetes. And, yes, it does appear that in people with diabetes, weight loss may be more difficult than in people without diabetes, as was first suggested by Wing et al. Should the focus of nutrition therapy for type 2 diabetes be on weight loss or improved blood glucose control? Another issue that makes weight loss even more of a dilemma is the effect of intentional weight loss on mortality in type 2 diabetes. 25 reported that people with diabetes who had an intentional weight loss in the Cancer Prevention Study I experienced a 25% reduction in total mortality and a 28% reduction in cardiovascular disease-plus-diabetes mortality. Until all the dilemmas are solved, what are appropriate messages concerning weight loss for people with diabetes? These results highlight the importance of counseling people with diabetes to increase physical activity and improve fitness, not only as a means of controlling weight, but also for the benefits of fitness that are independent of weight loss.
Type 2 Diabetes: How to Lose Weight. Weight loss is a common recommendation for treatment for type 2 diabetes. By losing weight, people with type 2 diabetes can become less insulin resistant, and they’re able to use insulin better. If you’ve recently been diagnosed with type 2 diabetes and you're overweight, you should get started as soon as possible on a weight loss plan. It is important to work with a registered dietitian to help you figure out a plan that will work for you—a healthy meal plan , physical activity , and realistic goals will help you reach a healthy weight. Lower your cholesterol levels (especially important for people with type 2 diabetes) Physical activity can help with weight loss, and in the article on exercising when you have type 2 diabetes , you can learn about how to start an exercise plan. Losing weight can help lower your body’s insulin resistance, but if it doesn’t help you achieve better blood glucose control, that doesn’t mean you’ve failed—or that you should give up. Losing weight and then maintaining a healthy weight are healthy choices for life—whether you have type 2 diabetes or not. Type 2 Diabetes: An Essential Guide for the newly Diagnosed.
My mom has type 2 diabetes and is overweight and her doctor recommended a new drug called Byetta. Is this medication safe and can it help my mom? Exenatide (brand name: Byetta) is a safe and effective medication for people with type 2 diabetes. Some people lose weight on this medication (on average, about 10 pounds in a year). Although the weight lose isn't dramatic, weight lose is preferable to weight gain, which is associated with some diabetes drugs, such as sulfonylureas and insulin. Some people experience nausea or stomach upset with the medicine, but this usually gets better with time. This is still a relatively new drug - the Food and Drug Administration approved it in 2005 - so all the potential long-term side effects aren't yet known. Pancreatitis is rare and no definitive link has been established between Byetta and the disease. You should know that people with diabetes have higher rates of pancreatitis due to their diabetes than the regular population. And, of course, people considering this medication should discuss any concerns they have with their doctor. I had several bouts with low blood sugar and did not lose weight.
Over the years, three diabetes treatments with entirely new modes of action were approved: exenatide injection (Byetta®, for people with type 2 diabetes), pramlintide injection (Symlin®, as an add-on to insulin therapy for people with type 1 or type 2 diabetes) and Sitagliptin (Januvia® also for people with type 2 diabetes). "New is not necessarily better, but these are additional weapons in the armament," says Nora Saul, MS, CDE, RD, LDN, Manager of Education Services at Joslin Diabetes Center. Some diabetes medications help the pancreas release more insulin (if you have type 2 diabetes), others help cells use insulin better, and others keep the liver from releasing too much glucose. “These three medications led the way for others being added to the list of available diabetes medications. Since then, many other additional medications have been added,” says Saul, “New to the list are Victoza, Bydureon, Tradjenta and Onglyza.” Since type 2 diabetes is progressive, what works for some people for a period of time may lose effectiveness. For example, some people with type 2 diabetes may start treating the chronic disease with oral medications, and then subsequently discover that insulin would give them more control. The following are the five new medical options that enhance blood glucose control for people with type 1 or type 2 diabetes: Is for those with type 2 diabetes who have been unable to control blood glucose with oral medicines. Is intended for those with type 1 or type 2 diabetes who use insulin. Is to never mix with insulin in one syringe; which creates the need for an additional injection for the patient. Used for better glucose control, reduction in blood glucose spikes, reduction in food intake, whichleads to weight loss. Are for type 2 diabetes.
Drug helps patients with diabetes lose weight. Among overweight and obese patients with type 2 diabetes, daily injection of the diabetes drug liraglutide with a modified insulin pen device, in addition to diet and exercise, resulted in greater weight loss over 56 weeks compared with placebo, according to a study in the August 18 issue of JAMA. Weight loss is recommended for patients with type 2 diabetes . Liraglutide is a medication approved for the treatment of type 2 diabetes (administered once daily at doses of 1.2 mg and 1.8 mg). Average weight loss was 6.0 percent (14.1 lbs.) with liraglutide (3.0-mg dose), 4.7 percent (11 lbs.) with liraglutide (1.8-mg dose), and 2.0 percent (4.8 lbs.) with placebo. Weight loss of 5 percent or greater occurred in 54.3 percent with liraglutide (3.0 mg) and 40.4 percent with liraglutide (1.8 mg) vs 21.4 percent with placebo. Weight loss greater than 10 percent occurred in 25.2 percent with liraglutide (3.0 mg) and 15.9 percent with liraglutide (1.8 mg) vs 6.7 percent with placebo. "To our knowledge, this is the first study specifically designed to investigate the efficacy of liraglutide for weight management in patients with type 2 diabetes and also the first study to investigate liraglutide at the higher 3.0-mg dose in a population with type 2 diabetes ," the authors write. Liraglutide augments weight loss in pre-type 2 diabetes. (Health Day)—For patients at high risk of type 2 diabetes mellitus (T 2 DM) and cardiovascular disease (CVD), liraglutide in additional to calorie restriction is associated with more weight loss and improvements in insulin .
"A number of drugs used to treat Type 2 diabetes tend to produce weight loss as one of their effects," said Katz, who was not involved in the study. For the study, Wilding and colleagues randomly selected 3,731 obese and overweight adults to take daily injections of Victoza or a placebo. The researchers found that almost two-thirds of those taking Victoza lost 5 percent or more of their body weight, and one-third lost 10 percent or more. Among those taking the placebo, 27 percent lost 5 percent of their body weight or more, and one in 10 lost 10 percent or more. People taking Victoza also saw a drop in their blood sugar, blood pressure and cholesterol, the study found. Food and Drug Administration to approve Victoza for weight loss. The most common side effects were nausea and diarrhea. Most of these were mild and short-lived, the researchers said. Gallbladder and pancreas problems (pancreatitis) were more common among those taking Victoza, but the numbers were small.